Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,078 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saußele S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK). Proetel U, et al. Among authors: schreiber a. Ann Hematol. 2014 Jul;93(7):1167-76. doi: 10.1007/s00277-014-2041-0. Ann Hematol. 2014. PMID: 24658964 Free PMC article. Clinical Trial.
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.
Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, Hossfeld DK, Kolb HJ, Hochhaus A, Hasford J, Hehlmann R; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK). Kalmanti L, et al. Among authors: schreiber a. Ann Hematol. 2014 Jan;93(1):71-80. doi: 10.1007/s00277-013-1937-4. Epub 2013 Oct 27. Ann Hematol. 2014. PMID: 24162333 Free PMC article.
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saußele S, Hochhaus A. Hehlmann R, et al. Among authors: schreiber a. J Clin Oncol. 2014 Feb 10;32(5):415-23. doi: 10.1200/JCO.2013.49.9020. Epub 2013 Dec 2. J Clin Oncol. 2014. PMID: 24297946 Clinical Trial.
Endovascular coils extrusion after internal carotid artery occlusion: From management to follow-up.
Vinciguerra A, Turri-Zanoni M, Ferrari M, Mattavelli D, Giorgianni A, Fazio E, Pierro FD, Rampinelli V, Gazzini L, Verillaud B, Schreiber A, Calabrese L, Bignami M, Battaglia P, Nicolai P, Castelnuovo P, Herman P. Vinciguerra A, et al. Among authors: schreiber a. Int Forum Allergy Rhinol. 2024 May 1. doi: 10.1002/alr.23357. Online ahead of print. Int Forum Allergy Rhinol. 2024. PMID: 38690609
[After the pandemic is before the pandemic: And how interdisciplinary research can help here].
Ly YT, Arndt F, Boschert AL, Pavletić B, Webner F, Kohl A, Grübbel H, Soltau J, Talai I, Diallo MD, Westhoff A, Schreiber A, Hecking T, Duschek F, Grünewald K, Meller F, Biedermann J, Rinderknecht F, Kraft W, Schmeling D, Jordan J, Moeller R. Ly YT, et al. Among authors: schreiber a. Laryngorhinootologie. 2024 Mar 12. doi: 10.1055/a-2249-4201. Online ahead of print. Laryngorhinootologie. 2024. PMID: 38471543 German.
1,078 results